Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02326129 · ClinicalTrials.gov registry record
Novel Biomarker for Development of T2D
A clinical trial, sponsored by Duke University.
- Completed
- Registry status
- 202
- Enrollment target
NCT02326129 is a clinical trial that has completed, run by Duke University. The registered enrollment target is 202 participants.
The verdict
NCT02326129 has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- 202 participants
- Enrollment target
Study Summary
The investigators wants to determine if 11β-HSD1 activity will be positively associated, and 5α-reductase activity negatively associated, with (a) degree of insulin resistance defined by the homeostatic model assessment of insulin resistance index (HOMA-IR) and (b) worsening glycemic control defined by higher HbA1c and impaired fasting glucose in a group of obese children and young adults with or without type 2 diabetes compared to lean children and young adults without diabetes. The investigators also want to identify key metabolic signatures associated with diabetes using metabolomic profiling.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 202 participants |
| Start Date | 2015-02 |
| Est. Completion | 2023-04-05 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02326129
The ClinicalTrials.gov registry entry for NCT02326129 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 202 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT02326129 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02326129 about?
NCT02326129 is a clinical study titled "Novel Biomarker for Development of T2D". The investigators wants to determine if 11β-HSD1 activity will be positively associated, and 5α-reductase activity negatively associated, with (a) degree of insulin resistance defined by the homeostatic model assessment of insulin resistance index (HOMA-IR) and (b) worsening glycemic control defined...
What is the current status of trial NCT02326129?
This trial is currently completed. The enrollment target is 202 participants. The study started on 2015-02. Estimated completion is 2023-04-05.
Who is sponsoring clinical trial NCT02326129?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.